*Terms and conditions apply
Shown to reduce HbA1c by up to ~1.0–1.5 percentage points in trials.Source: Jastreboff et al., NEJM 2022; Pratley et al., Lancet 2018
Demonstrated improvements in LDL cholesterol and triglycerides compared with placebo.Source: Nauck & Meier, Lancet Diabetes Endocrinol 2019
Can lead to significant reductions in CRP, a key marker of inflammation.Source: Hattori et al., Cardiovascular Diabetology 2020
Can reduce liver fat content and improve ALT in people with metabolic dysfunction.Source: Armstrong et al., Lancet 2016
Associated with reduced risk of major cardiovascular events in people with elevated cardiometabolic risk.Source: Marso et al., NEJM 2016 (LEADER Trial)